SCHEMBL1491003

SCHEMBL1491003

Fc1[c]cccc1-c1ccc(Br)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 3/20 0.38
PTPRC P08575 1/20 0.34
SLC6A3 Q01959 1/20 0.34
PLK4 O00444 1/20 0.33
AURKA O14965 1/20 0.33
JAK2 O60674 1/20 0.33
LCK P06239 1/20 0.33
CDK1 P06493 1/20 0.33
CSF1R P07333 1/20 0.33
LYN P07948 1/20 0.33
FGFR1 P11362 1/20 0.33
SRC P12931 1/20 0.33
PRKACA P17612 1/20 0.33
RPS6KB1 P23443 1/20 0.33
CDK2 P24941 1/20 0.33
MARK3 P27448 1/20 0.33
AKT1 P31749 1/20 0.33
AKT2 P31751 1/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9788256 0.83 PTGS2 (0.40) ALDH1A1SLC6A3LCKCSF1RFGFR1
SCHEMBL693994 0.81 ALDH1A1 (0.39) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL7805516 0.80 PTGS2 (0.36) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL433163 0.80 CYP1A2 (0.38) ALDH1A1SLC6A3NPC1RAB9ASMN1; SMN2
SCHEMBL1431628 0.79 ALDH1A1 (0.41) ALDH1A1MAPK1PTPRCSLC6A3PLK4
SCHEMBL9667400 0.78 MAPK1 (0.39) ALDH1A1MAPK1PTPRCSLC6A3PLK4
SCHEMBL4673934 0.78 ALDH1A1 (0.39) ALDH1A1MAPK1PTPRCSLC6A3PLK4
SCHEMBL1490906 0.76 ALDH1A1 (0.33) ALDH1A1MAPK1CYP2A6MEN1KMT2A
SCHEMBL21647122 0.76 ALDH1A1 (0.38) ALDH1A1MAPK1PTPRCSLC6A3PLK4
SCHEMBL4364998 0.76 MAPT (0.39) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946261-B2 Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of Alzheimer's disease COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-02-03 US disclosed
EP-2675790-A1 SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE Council of Scientific & Industrial Research (IN) 2013-12-25 EP disclosed
US-20130324573-A1 SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-12-05 US disclosed
WO-2012111021-A1 SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860) (IN) 2012-08-23 WO disclosed
EP-2477982-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2012-07-25 EP disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130324573-A1 SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE ACHE, BCHE, CHAT ALDH1A1 1202/4885MAPK1 1625/4885PTPRC 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.